Federico M. Asch

Federico M. Asch

Auto-generated profile, based on publicly available information

Federico M. Asch

Georgetown University

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2021 in Circulation
Verified
Journal Article
Open access
PDF file
SKSaibal Kar
Saibal Kar
SDShephal K. Doshi
Shephal K. Doshi
ASAshish Sadhu
Ashish Sadhu
RHRodney Horton
Rodney Horton
JOJose Osorio
Jose Osorio
OIOn behalf of the PINNACLE FLX Investigators
On behalf of the PINNACLE FLX Investigators
Background: Left atrial appendage (LAA) occlusion provides an alternative to oral anticoagulation for thromboembolic risk reduction in patients with nonvalvular atrial fibrillation. Since regulatory approval in 2015, the WATCHMAN device has been the only LAA closure device available for clinical use in the United States. The PINNACLE FLX study (Protection Against Embolism for Nonvalvular AF Patients: Investigational Device Evaluation of the Watchman FLX LAA Closure Technology) evaluated the safety and effectiveness of the next-generation WATCHMAN FLX LAA closure device in patients with nonvalvular atrial fibrillation in whom oral anticoagulation is indicated, but who have an appropriate rationale to seek a nonpharmaceutical alternative. Methods: This was a prospective, nonrandomized, multicenter US Food and Drug Administration study. The primary safety end point was the occurrence of one of the following events within 7 days after the procedure or by hospital discharge, whichever was later: death, ischemic stroke, systemic embolism, or device- or procedure-related events requiring cardiac surgery. The primary effectiveness end point was the incidence of effective LAA closure (peri-device flow ≤5 mm), as assessed by the echocardiography core laboratory at 12-month follow-up. Results: A total of 400 patients were enrolled. The mean age was 73.8±8.6 years and the mean CHA 2 DS 2 -VASc score was 4.2±1.5. The incidence of the primary safety end point was 0.5% with a 1-sided 95% upper CI of 1.6%, meeting the performance goal of 4.2% ( P <0.0001). The incidence of the primary effectiveness end point was 100%, with a 1-sided 95% lower CI of 99.1%, again meeting the performance goal of 97.0% ( P <0.0001). Device-related thrombus was reported in 7 patients, no patients experienced pericardial effusion requiring open cardiac surgery, and there were no device embolizations. Conclusions: LAA closure with this next-generation LAA closure device was associated with a low incidence of adverse events and a high incidence of anatomic closure. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02702271.

1 December 2019 in JACC
Verified
Journal Article
Open access
FAFederico M. Asch
Federico M. Asch
PGPaul A. Grayburn
Paul A. Grayburn
RSRobert J. Siegel
Robert J. Siegel
SKSaibal Kar
Saibal Kar
DLD. Scott Lim
D. Scott Lim
NWNeil J. Weissman
Neil J. Weissman
In the COAPT (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation) trial among patients with heart failure (HF) and moderate-to-severe (3+) or severe (4+) secondary mitral regurgitation, patients treated with transcatheter mitral valve repair (TMVr) through leaflet approximation had reduced rates of HF hospitalization and mortality compared with guideline-directed medical therapy (GDMT) alone. The purpose of this study was to describe the echocardiographic patient qualification process for the COAPT trial, baseline echocardiographic characteristics, changes over time, and the interaction between treatment group and echocardiographic parameters on clinical outcomes. A novel echocardiographic algorithm was implemented for grading mitral regurgitation severity during the screening process. Standardized echocardiograms were obtained at baseline and during regular follow-up intervals through 2 years, and were analyzed by a core laboratory. A total of 614 patients were randomized to TMVr plus maximally tolerated GDMT or GDMT alone. Mean baseline left ventricular (LV) ejection fraction was 31.3 ± 9.3%, LV end-diastolic volume was 192.7 ± 71 ml, and effective regurgitant orifice area was 0.41 ± 0.15 cm2. The beneficial effect of TMVr compared with GDMT alone was consistent in all echocardiographic subgroups, independent of the severity of LV dysfunction, LV dilatation, pulmonary hypertension, severity of tricuspid regurgitation, or individual mitral regurgitation characteristics. The LV ejection fraction decreased and the LV volumes progressively increased in both groups during follow-up, although less after TMVr (p < 0.05). HF patients in the COAPT trial with 3+ or 4+ secondary mitral regurgitation, selected using strict echocardiographic criteria, benefitted from TMVr with reduced 2-year rates of death and HF hospitalization. Strict application of these echocardiographic criteria should enable the COAPT results to be translated to clinical practice. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626079).

1 November 2019 in Journal of the American Society of Echocardiography
Verified
Journal Article
Closed access
FAFederico M. Asch
Federico M. Asch
TMTatsuya Miyoshi
Tatsuya Miyoshi
KAKarima Addetia
Karima Addetia
RCRodolfo Citro
Rodolfo Citro
MDMasao Daimon
Masao Daimon
JKJames Kirkpatrick
James Kirkpatrick

1 March 2016 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
FAFederico M. Asch
Federico M. Asch
EYEugene Yuriditsky
Eugene Yuriditsky
SPSiddharth K. Prakash
Siddharth K. Prakash
MRMary J. Roman
Mary J. Roman
JWJonathan W. Weinsaft
Jonathan W. Weinsaft
NWNeil J. Weissman
Neil J. Weissman

1 June 2021 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
FAFederico M. Asch
Federico M. Asch
VMVictor Mor-Avi
Victor Mor-Avi
DRDavid Rubenson
David Rubenson
SGSteven Goldstein
Steven Goldstein
MSMuhamed Saric
Muhamed Saric
RLRoberto M. Lang
Roberto M. Lang
Background: We have recently tested an automated machine-learning algorithm that quantifies left ventricular (LV) ejection fraction (EF) from guidelines-recommended apical views. However, in the point-of-care (POC) setting, apical 2-chamber views are often difficult to obtain, limiting the usefulness of this approach. Since most POC physicians often rely on visual assessment of apical 4-chamber and parasternal long-axis views, our algorithm was adapted to use either one of these 3 views or any combination. This study aimed to (1) test the accuracy of these automated estimates; (2) determine whether they could be used to accurately classify LV function. Methods: Reference EF was obtained using conventional biplane measurements by experienced echocardiographers. In protocol 1, we used echocardiographic images from 166 clinical examinations. Both automated and reference EF values were used to categorize LV function as hyperdynamic (EF>73%), normal (53%–73%), mildly-to-moderately (30%–52%), or severely reduced (<30%). Additionally, LV function was visually estimated for each view by 10 experienced physicians. Accuracy of the detection of reduced LV function (EF<53%) by the automated classification and physicians’ interpretation was assessed against the reference classification. In protocol 2, we tested the new machine-learning algorithm in the POC setting on images acquired by nurses using a portable imaging system. Results: Protocol 1: the agreement with the reference EF values was good (intraclass correlation, 0.86–0.95), with biases <2%. Machine-learning classification of LV function showed similar accuracy to that by physicians in most views, with only 10% to 15% cases where it was less accurate. Protocol 2: the agreement with the reference values was excellent (intraclass correlation=0.84) with a minimal bias of 2.5±6.4%. Conclusions: The new machine-learning algorithm allows accurate automated evaluation of LV function from echocardiographic views commonly used in the POC setting. This approach will enable more POC personnel to accurately assess LV function.

23 January 2006 in Echocardiography
Verified
Journal Article
Closed access
PDF file
FAFederico M. Asch
Federico M. Asch
SBSzymon P. Bieganski
Szymon P. Bieganski
JPJulio A. Panza
Julio A. Panza
NWNeil J. Weissman
Neil J. Weissman